Cipla invests $90 million in API plants; Isis gets EMA nod for California plant;

> In its annual report, India-based Cipla says it will invest about $89.9 million to build active pharmaceutical ingredients (API) facilities at Patalganga, Mumbai, Bengaluru, Karnataka, and Kurkumbh, Pune, India. Annual report

> The Medicines and Healthcare Products Regulatory Agency in the U.K. has updated its 45-year-old regulations over drug manufacturing and distribution. Story

> An Isis Pharmaceuticals plant in Carlsbad, CA, has received EMA approval in anticipation of launch in Europe of Kynamro, a lipid-lowering drug it is developing with Genzyme. Story

> Materia has extended for another decade an agreement with Sigma-Aldrich for global distribution of its catalyst technology. Item

And Finally... Japanese regulators have approved for distribution in Japan Teijin's Bonalon Jelly, the first time the osteoporosis drug has been manufactured in this form, the company says. Release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.

Roche's global manufacturing leader Pierre-Alain Ruffieux will take the reins and oversee the Moderna COVID-19 vaccine collaboration.